AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that a patent has been awarded titled “Diminishing Viral Gene Expression by Promoter Replacement” by the U.S. Patent and Trademark Office focusing on adenoviral vector development, which is the most commercially important type of viral vector used in the field of gene therapy. The patent, U.S. Patent No 7,244,617, is one of numerous patents, pending or issued, that Introgen has licensed exclusively from The University of Texas System M. D. Anderson Cancer Center.